clinical trial · NCT07409428
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed·phase3·recruiting·n = 240
Relapsed/Refractory Diffuse Large B-Cell LymphomaHMPL-760HMPL-760 PlaceboR-GemOx
brief summary
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
started
Mar 20, 2026
primary completion
Apr 30, 2028
completion
Dec 30, 2028
last updated
Apr 1, 2026
detailed description
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
official title
A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol